114 related articles for article (PubMed ID: 3816969)
1. Phenethylamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity.
Rasmussen K; Glennon RA; Aghajanian GK
Eur J Pharmacol; 1986 Dec; 132(1):79-82. PubMed ID: 3816969
[TBL] [Abstract][Full Text] [Related]
2. Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity.
Rasmussen K; Aghajanian GK
Neuropsychopharmacology; 1988 May; 1(2):101-7. PubMed ID: 2908015
[TBL] [Abstract][Full Text] [Related]
3. Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2 antagonists.
Rasmussen K; Aghajanian GK
Brain Res; 1986 Oct; 385(2):395-400. PubMed ID: 3096493
[TBL] [Abstract][Full Text] [Related]
4. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse.
Glennon RA; Titeler M; Lyon RA
Pharmacol Biochem Behav; 1988 Jul; 30(3):597-601. PubMed ID: 3211969
[TBL] [Abstract][Full Text] [Related]
5. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
Titeler M; Herrick K; Lyon RA; McKenney JD; Glennon RA
Eur J Pharmacol; 1985 Oct; 117(1):145-6. PubMed ID: 4085543
[No Abstract] [Full Text] [Related]
6. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
Titeler M; Lyon RA; Glennon RA
Psychopharmacology (Berl); 1988; 94(2):213-6. PubMed ID: 3127847
[TBL] [Abstract][Full Text] [Related]
7. Potent agonist activity of DOB at 5-HT2 receptors in guinea pig trachea.
Heller WA; Baraban JM
Eur J Pharmacol; 1987 Jun; 138(1):115-7. PubMed ID: 3622603
[TBL] [Abstract][Full Text] [Related]
8. Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors.
Buckholtz NS; Zhou DF; Freedman DX
Life Sci; 1988; 42(24):2439-45. PubMed ID: 3374263
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic regulation of noradrenergic coerulean neurons: electrophysiological evidence for the involvement of 5-HT2 receptors.
Gorea E; Adrien J
Eur J Pharmacol; 1988 Sep; 154(3):285-91. PubMed ID: 3234483
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.
Pierce PA; Peroutka SJ
J Pharmacol Exp Ther; 1988 Dec; 247(3):918-25. PubMed ID: 3204523
[TBL] [Abstract][Full Text] [Related]
11. Possible involvement of serotonin receptors in the facilitatory effect of a hallucinogenic phenethylamine on single facial motoneurons.
Penington NJ; Reiffenstein RJ
Can J Physiol Pharmacol; 1986 Oct; 64(10):1302-9. PubMed ID: 3801984
[TBL] [Abstract][Full Text] [Related]
12. (R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes.
Peroutka SJ; Hamik A; Harrington MA; Hoffman AJ; Mathis CA; Pierce PA; Wang SS
Mol Pharmacol; 1988 Oct; 34(4):537-42. PubMed ID: 3173334
[TBL] [Abstract][Full Text] [Related]
13. Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs.
Sanders-Bush E; Breeding M
Psychopharmacology (Berl); 1991; 105(3):340-6. PubMed ID: 1665919
[TBL] [Abstract][Full Text] [Related]
14. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex.
Pierce PA; Peroutka SJ
Psychopharmacology (Berl); 1989; 97(1):118-22. PubMed ID: 2540505
[TBL] [Abstract][Full Text] [Related]
15. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
Sanders-Bush E; Burris KD; Knoth K
J Pharmacol Exp Ther; 1988 Sep; 246(3):924-8. PubMed ID: 2843634
[TBL] [Abstract][Full Text] [Related]
16. Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment.
Leysen JE; Janssen PF; Niemegeers CJ
Eur J Pharmacol; 1989 Apr; 163(1):145-9. PubMed ID: 2545460
[TBL] [Abstract][Full Text] [Related]
17. The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administration.
Owens MJ; Knight DL; Ritchie JC; Nemeroff CB
J Pharmacol Exp Ther; 1991 Feb; 256(2):795-800. PubMed ID: 1847213
[TBL] [Abstract][Full Text] [Related]
18. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.
Lyon RA; Davis KH; Titeler M
Mol Pharmacol; 1987 Feb; 31(2):194-9. PubMed ID: 3543649
[TBL] [Abstract][Full Text] [Related]
19. Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo.
Done CJ; Sharp T
Br J Pharmacol; 1992 Sep; 107(1):240-5. PubMed ID: 1422575
[TBL] [Abstract][Full Text] [Related]
20. R(-)-2,5-dimethoxy-4-77 bromoamphetamine [77Br-R(-)DOB]: a novel radioligand which labels a 5-HT binding site subtype.
Wang SS; Mathis CA; Peroutka SJ
Psychopharmacology (Berl); 1988; 94(3):431-2. PubMed ID: 3357926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
